1.
Kidney Biopsy Features Most Predictive of Clinical Outcomes in the Spectrum of Minimal Change Disease and Focal Segmental Glomerulosclerosis. Zee J, Liu Q, Smith AR, Hodgin JB, Rosenberg A, Gillespie BW, Holzman LB, Barisoni L, Mariani LH; Nephrotic Syndrome Study Network (NEPTUNE).
J Am Soc Nephrol. 2022 May 17:ASN.2021101396. doi: 10.1681/ASN.2021101396. Online ahead of print.
PMID: 35581011
2.
Transitioning From S1P Receptor Modulators to B Cell-Depleting Therapies in Multiple Sclerosis: Clinical, Radiographic, and Laboratory Data. Rowles WM, Hsu WY, McPolin K, Li A, Merrill S, Guo CY, Green AJ, Gelfand JM, Bove RM.
Neurol Neuroimmunol Neuroinflamm. 2022 May 17;9(4):e1183. doi: 10.1212/NXI.0000000000001183. Print 2022 Jul.
PMID: 35581005
3.
Innate Immune Cell-Related Pathology in the Thalamus Signals a Risk for Disability Progression in Multiple Sclerosis. Misin O, Matilainen M, Nylund M, Honkonen E, Rissanen E, Sucksdorff M, Airas L.
Neurol Neuroimmunol Neuroinflamm. 2022 May 17;9(4):e1182. doi: 10.1212/NXI.0000000000001182. Print 2022 Jul.
PMID: 35581004
4.
Exploring in vivo multiple sclerosis brain microstructural damage through T1w/T2w ratio: a multicentre study. Margoni M, Pagani E, Meani A, Storelli L, Mesaros S, Drulovic J, Barkhof F, Vrenken H, Gallo A, Bisecco A, Pareto D, Sastre-Garriga J, Ciccarelli O, Yiannakas M, Palace J, Preziosa P, Rocca MA, Filippi M; MAGNIMS Study Group.
J Neurol Neurosurg Psychiatry. 2022 May 17:jnnp-2022-328908. doi: 10.1136/jnnp-2022-328908. Online ahead of print.
PMID: 35580993
5.
Validity and sensitivity of Canadian normative data for the minimal assessment of cognitive function in multiple sclerosis (MACFIMS) battery. Berard JA, Walker LAS.
Mult Scler Relat Disord. 2022 May 11;63:103865. doi: 10.1016/j.msard.2022.103865. Online ahead of print.
PMID: 35580469
6.
The innovative animal monitoring device for experimental autoimmune encephalomyelitis (“I AM D EAE”): A more detailed evaluation for improved results. Osorio-Querejeta I, Alberro A, Suárez J, Sáenz-Cuesta M, Oregi A, Moles L, Muñoz-Culla M, Otaegui D.
Mult Scler Relat Disord. 2022 May 11;63:103836. doi: 10.1016/j.msard.2022.103836. Online ahead of print.
PMID: 35580468
7.
An epidemiological analysis of multiple sclerosis patients hospitalized in the United States. Ramphul K, Lohana P, Verma R, Kumar N, Ramphul Y, Lohana A, Sombans S, Mejias SG, Kumari K, Joynauth J.
Mult Scler Relat Disord. 2022 Apr 30;63:103840. doi: 10.1016/j.msard.2022.103840. Online ahead of print.
PMID: 35580467 No abstract available.
8.
Effects and optimal dosage of resistance training on strength, functional capacity, balance, general health perception, and fatigue in people with multiple sclerosis: a systematic review and meta-analysis. Andreu-Caravaca L, Ramos-Campo DJ, Chung LH, Martínez-Rodríguez A, Rubio-Arias JÁ.
Disabil Rehabil. 2022 May 17:1-13. doi: 10.1080/09638288.2022.2069295. Online ahead of print.
PMID: 35579532
9.
Effectiveness and Safety of Early High-Efficacy Versus Escalation Therapy in Relapsing-Remitting Multiple Sclerosis in Argentina. Rojas JI, Patrucco L, Alonso R, Garcea O, Deri N, Carnero Contentti E, Lopez PA, Pettinicchi JP, Caride A, Cristiano E.
Clin Neuropharmacol. 2022 May-Jun 01;45(3):45-51. doi: 10.1097/WNF.0000000000000503. Epub 2022 Apr 14.
PMID: 35579483
10.
Can We Treat Neurodegenerative Proteinopathies by Enhancing Protein Degradation? Engelender S, Stefanis L, Oddo S, Bellucci A.
Mov Disord. 2022 May 17. doi: 10.1002/mds.29058. Online ahead of print.
PMID: 35579450
11.
Opportunities and challenges: mesenchymal stem cells in the treatment of multiple sclerosis. Zhang Y, Gu J, Wang X, Li L, Fu L, Wang D, Wang X, Han X.
Int J Neurosci. 2022 May 17:1-14. doi: 10.1080/00207454.2022.2042690. Online ahead of print.
PMID: 35579409
12.
Neuromodulation for lower urinary tract symptoms in special populations. Wang CN, Chung DE.
Neurourol Urodyn. 2022 May 17. doi: 10.1002/nau.24954. Online ahead of print.
PMID: 35579275 Review.
13.
Initial experience using the Axonics sacral neuromodulation system in patients with multiple sclerosis. Chen A, Kapur A, Mossack S, Weissbart SJ, Kim JM.
Neurourol Urodyn. 2022 May 17. doi: 10.1002/nau.24955. Online ahead of print.
PMID: 35579263
14.
New insights into the immunologic role of oligodendrocyte lineage cells in demyelination diseases. Li H, Chen Y, Niu J, Yi C.
J Biomed Res. 2022 Apr 28:1-10. doi: 10.7555/JBR.36.20220016. Online ahead of print.
PMID: 35578762
15.
Circulating neurofilament is linked with morbid obesity, renal function, and brain density. Rebelos E, Rissanen E, Bucci M, Jääskeläinen O, Honka MJ, Nummenmaa L, Moriconi D, Laurila S, Salminen P, Herukka SK, Singhal T, Nuutila P.
Sci Rep. 2022 May 12;12(1):7841. doi: 10.1038/s41598-022-11557-2.
PMID: 35551210 Free PMC article.
16.
Introduction of loxP sites by electroporation in the mouse genome; a simple approach for conditional allele generation in complex targeting loci. Bernas G, Ouellet M, Barrios A, Jamann H, Larochelle C, Lévy É, Schmouth JF.
BMC Biotechnol. 2022 May 12;22(1):14. doi: 10.1186/s12896-022-00744-8.
PMID: 35549895 Free PMC article.
17.
Do we need more clinical trials in secondary progressive MS? Lechner-Scott J, Yeh A, Levy M, Hawkes C, Giovannoni G.
Mult Scler Relat Disord. 2022 Apr;60:103790. doi: 10.1016/j.msard.2022.103790. Epub 2022 Apr 4.
PMID: 35398712 No abstract available.
18.
Effects of flexible scheduling and virtual visits on burnout for clinicians. Sullivan AB, Davin SA, Lapin B, Schuster AT, Dweik RA, Murray KF, Rehm SJ, Machado AG.
Mult Scler Relat Disord. 2022 Apr;60:103705. doi: 10.1016/j.msard.2022.103705. Epub 2022 Feb 25.
PMID: 35279627
19.
A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials. Sforzini L, Worrell C,
Schmidt ME, van de Ketterij E, Woo K, Flossbach Y, Ramos-Quiroga JA, Savitz AJ, Pariante CM.
Mol Psychiatry. 2022 Mar;27(3):1286-1299. doi: 10.1038/s41380-021-01381-x. Epub 2021 Dec 15.
PMID: 34907394 Free PMC article. Review.
1.
Rare co-occurrence of multiple sclerosis and Wilson’s disease – case report. Despotov K, Klivényi P, Nagy I, Pálvölgyi A, Vécsei L, Rajda C.
BMC Neurol. 2022 May 16;22(1):178. doi: 10.1186/s12883-022-02691-5.
PMID: 35578211
2.
Motor evoked potentials for multiple sclerosis, a multiyear follow-up dataset. Yperman J, Popescu V, Van Wijmeersch B, Becker T, Peeters LM.
Sci Data. 2022 May 16;9(1):207. doi: 10.1038/s41597-022-01335-0.
PMID: 35577808
3.
Increasing incidence and prevalence of multiple sclerosis in the Greater Hobart cohort of Tasmania, Australia. Simpson-Yap S, Atvars R, Blizzard L, van der Mei I, Taylor BV.
J Neurol Neurosurg Psychiatry. 2022 May 16:jnnp-2022-328932. doi: 10.1136/jnnp-2022-328932. Online ahead of print.
PMID: 35577508
4.
The influence of disease-modifying therapy on hidden disability burden in people with newly diagnosed relapsing-remitting multiple sclerosis. Glasmacher SA, Kearns PK, Hassan Z, Connick P, Tauber S, Reetz K, Foley P, Chandran S; FutureMS Consortium.
Mult Scler Relat Disord. 2022 Apr 30;63:103837. doi: 10.1016/j.msard.2022.103837. Online ahead of print.
PMID: 35576728
5.
Disease modifying therapy management of multiple sclerosis after stem cell therapies: A retrospective case series. Manzano GS, Holroyd KB, Kaplan T, Bhattacharyya S, Chitnis T, Hotan G, Zurawski J, Galetta KM, Mateen FJ.
Mult Scler Relat Disord. 2022 May 10;63:103861. doi: 10.1016/j.msard.2022.103861. Online ahead of print.
PMID: 35576727
6.
Involvement of age-associated B cells in EBV-triggered autoimmunity. Sachinidis A, Garyfallos A.
Immunol Res. 2022 May 16. doi: 10.1007/s12026-022-09291-y. Online ahead of print.
PMID: 35575824
7.
Association of Brain Atrophy With Disease Progression Independent of Relapse Activity in Patients With Relapsing Multiple Sclerosis. Cagol A, Schaedelin S, Barakovic M, Benkert P, Todea RA, Rahmanzadeh R, Galbusera R, Lu PJ, Weigel M, Melie-Garcia L, Ruberte E, Siebenborn N, Battaglini M, Radue EW, Yaldizli Ö, Oechtering J, Sinnecker T, Lorscheider J, Fischer-Barnicol B, Müller S, Achtnichts L, Vehoff J, Disanto G, Findling O, Chan A, Salmen A, Pot C, Bridel C, Zecca C, Derfuss T, Lieb JM, Remonda L, Wagner F, Vargas MI, Du Pasquier R, Lalive PH, Pravatà E, Weber J, Cattin PC, Gobbi C, Leppert D, Kappos L, Kuhle J, Granziera C.
JAMA Neurol. 2022 May 16. doi: 10.1001/jamaneurol.2022.1025. Online ahead of print.
PMID: 35575778
8.
Vitamin D: sources, physiological role, biokinetics, deficiency, therapeutic use, toxicity, and overview of analytical methods for detection of vitamin D and its metabolites. Janoušek J, Pilařová V, Macáková K, Nomura A, Veiga-Matos J, Silva DDD, Remião F, Saso L, Malá-Ládová K, Malý J, Nováková L, Mladěnka P.
Crit Rev Clin Lab Sci. 2022 May 16:1-38. doi: 10.1080/10408363.2022.2070595. Online ahead of print.
PMID: 35575431
9.
Stick or twist? Cost-effectiveness of siponimod compared with continuing existing disease-modifying therapies in the treatment of active secondary progressive multiple sclerosis in the UK. Montgomery S, Woodhouse F, Vudumula U, Gudala K, Duddy M, Kroes M.
J Med Econ. 2022 May 16:1-52. doi: 10.1080/13696998.2022.2078103. Online ahead of print.
PMID: 35575251
10.
Anti-CGRP therapies for migraine in multiple sclerosis patients. Gonzalez-Martinez A, Bose G, Chitnis T.
Mult Scler. 2022 May 14:13524585221096353. doi: 10.1177/13524585221096353. Online ahead of print.
PMID: 35575242 No abstract available.
11.
Preserved T cell responses to SARS-CoV-2 in anti-CD20 treated multiple sclerosis. Schwarz T, Otto C, Jones TC, Pache F, Schindler P, Niederschweiberer M, Schmidt FA, Drosten C, Corman VM, Ruprecht K.
Mult Scler. 2022 May 14:13524585221094478. doi: 10.1177/13524585221094478. Online ahead of print.
PMID: 35575234
12.
Mapping the risk of infections in patients with multiple sclerosis: A multi-database study in the United Kingdom Clinical Practice Research Datalink GOLD and Aurum. Leung MW, Bazelier MT, Souverein PC, Uitdehaag BM, Klungel OH, Leufkens HG, Pajouheshnia R.
Mult Scler. 2022 May 14:13524585221094218. doi: 10.1177/13524585221094218. Online ahead of print.
PMID: 35575214
13.
The role of body fat in multiple sclerosis susceptibility and severity: A Mendelian randomisation study. Almramhi MM, Storm CS, Kia DA, Coneys R, Chhatwal BK, Wood NW.
Mult Scler. 2022 May 14:13524585221092644. doi: 10.1177/13524585221092644. Online ahead of print.
PMID: 35575213
14.
Teriflunomide normalizes anti-anxiety effect in anti-ANXA2 APS mice model teriflunomide in anti-ANXA2 mice model. Zmira O, Gofrit SG, Aharoni SA, Weiss R, Shavit-Stein E, Chapman J.
Lupus. 2022 Jun;31(7):855-863. doi: 10.1177/09612033221095150.
PMID: 35575144
1.
The timed 25-foot walk is a more sensitive outcome measure than the EDSS for PPMS trials: an analysis of the PROMISE clinical trial dataset. Koch MW, Mostert J, Repovic P, Bowen JD, Comtois J, Strijbis E, Uitdehaag B, Cutter G.
J Neurol. 2022 May 16. doi: 10.1007/s00415-022-11171-2. Online ahead of print.
PMID: 35570237
2.
Effects of Long-term Hybrid Assistive Limb Use on Gait in Patients with Amyotrophic Lateral Sclerosis. Morioka H, Murata K, Sugisawa T, Shibukawa M, Ebina J, Sawada M, Hanashiro S, Nagasawa J, Yanagihashi M, Hirayama T, Uchi M, Kawabe K, Ebihara S, Murakami Y, Nakajima T, Kano O.
Intern Med. 2022;61(10):1479-1484. doi: 10.2169/internalmedicine.8030-21. Epub 2022 May 15.
PMID: 35569927
3.
Dimethyl fumarate: A review of preclinical efficacy in models of neurodegenerative diseases. Majkutewicz I.
Eur J Pharmacol. 2022 May 12:175025. doi: 10.1016/j.ejphar.2022.175025. Online ahead of print.
PMID: 35569547 Review.
4.
Myelinated axons are the primary target of hemin-mediated oxidative damage in a model of the central nervous system. Baldacchino K, Peveler WJ, Lemgruber L, Smith RS, Scharler C, Hayden L, Komarek L, Lindsay SL, Barnett SC, Edgar JM, Linington C, Thümmler K.
Exp Neurol. 2022 May 12:114113. doi: 10.1016/j.expneurol.2022.114113. Online ahead of print.
PMID: 35569511
5.
The lower basal metabolic rate is associated with increased risk of osteosarcopenia in postmenopausal women. Maghbooli Z, Mozaffari S, Dehghani Y, Rezaei Amirkiasar P, Malekhosseini AA, Rezanejad M, Holick MF.
BMC Womens Health. 2022 May 14;22(1):171. doi: 10.1186/s12905-022-01754-6.
PMID: 35568898
Nejnovější komentáře